As per the WHO report (2020), around 0.8 million people commit suicide every year, and more than 90% of these had a psychiatric diagnosis (2, 3)
Like caffeine, it could amplify the GI side effects of GLP-1 medications
It's not just about avoiding severe problems like neurological damage, which the article mentions, but about enhancing daily quality of life
Repurposing a drug to treat other health issues isn't an uncommon phenomenon, with semaglutide already being used to tackle type 2 diabetes and obesity
These effects become therapeutically interesting in obesity because they suggest that glucagon receptor activation could complement appetite suppression by increasing caloric expenditure and improving hepatic lipid handling
These were patients who: already had atherosclerotic cardiovascular disease or heart failure were 65 or older or had moderate kidney problems